Market Overview

UPDATE: Wedbush Raises PT to $32 on Pacira Pharmaceuticals on Long-Term Outlook

Share:
Related PCRX
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
20 Biggest Mid-Day Gainers For Wednesday
4 Biotech Stocks to Watch (GuruFocus)

Wedbush maintained Pacira Pharmaceuticals (NASDAQ: PCRX) with an Outperform rating and raised the price target from $23.00 to $32.00.

Wedbush said, "As already preannounced, PCRX reported Q4 EXPAREL sales of $7.8MM, ahead of our original $7.0MM estimate. Q4 total revenues were $10.5MM and GAAP EPS loss was ($0.50) versus our ($0.32) and Street's ($0.42) estimates. The company ended Q4 with about $42.6MM in cash and including proceeds from the January convertible debt offering, we estimate current cash of about $123MM. We project runway well into potential profitability, which we model to occur in 2014."

Pacira Pharmaceuticals closed at $25.30 on Wednesday.

Latest Ratings for PCRX

DateFirmActionFromTo
Mar 2017WedbushReiteratesOutperform
Feb 2017Canaccord GenuityInitiates Coverage OnBuyBuy
Jan 2017H.C. WainwrightInitiates Coverage OnBuy

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings

 

Related Articles (PCRX)

View Comments and Join the Discussion!